| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
CCT129202 (CCT-129202), an imidazopyridine compound, is a potent and ATP-competitive pan-Aurora inhibitor with potential antitumor activity. It inhibits Aurora A, Aurora B and Aurora C with IC50s of 0.042 μM, 0.198 μM and 0.227 μM, respectively. CCT129202 shows potent in vitro antiproliferative activity and high in vivo antitumor efficacy.
| ln Vitro |
Apoptosis results from the increase of z4N-containing human tumor cells brought on by CCT129202. It is discovered that CCT129202 induces apoptosis, with GI50 values ranging from 0.08 to 1.7 μM. Human tumor cells treated with CCT120202 exhibit spindle abnormalities, abrogation of nocodazole-induced mitotic arrest, and a delay in mitosis. H2F-DependentTK1Down-regulation, Rb Hypophosphorylation, and p21Up-regulation are all caused by CCT129202[1].
|
||
|---|---|---|---|
| ln Vivo |
CCT129202 is administered intraperitoneally (i.p.) to nude mice to suppress the growth of HCT116 xenografts. CCT129202 induces the cyclin-dependent kinase inhibitor p21. Thymidine kinase 1 transcription was reduced as a result of Rb hypophosphorylation and E2F suppression brought on by CCT129202's up-regulation of p21 in HCT116 cells[1].
|
||
| Animal Protocol |
|
||
| References |
[1]. Chan F, et al. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3147-57
|
| Molecular Formula |
C23H25CLN8OS
|
|
|---|---|---|
| Molecular Weight |
497.02
|
|
| CAS # |
942947-93-5
|
|
| Related CAS # |
|
|
| SMILES |
O=C(NC1=NC=CS1)CN2CCN(C3=C4C(NC(C5=CC=C(N(C)C)C=C5)=N4)=NC=C3Cl)CC2
|
|
| InChi Key |
QYKHWEFPFAGNEV-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C23H25ClN8OS/c1-30(2)16-5-3-15(4-6-16)21-28-19-20(17(24)13-26-22(19)29-21)32-10-8-31(9-11-32)14-18(33)27-23-25-7-12-34-23/h3-7,12-13H,8-11,14H2,1-2H3,(H,25,27,33)(H,26,28,29)
|
|
| Chemical Name |
2-(4-(6-chloro-2-(4-(dimethylamino)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)-N-(thiazol-2-yl)acetamide
|
|
| Synonyms |
CCT-129202; CCT 129202; CCT129202.
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0120 mL | 10.0600 mL | 20.1199 mL | |
| 5 mM | 0.4024 mL | 2.0120 mL | 4.0240 mL | |
| 10 mM | 0.2012 mL | 1.0060 mL | 2.0120 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA